| Name | Title | Contact Details |
|---|
AgBiome is a biotechnology company using new knowledge of the plant-associated microbiome to create innovative products for agriculture. We have compiled the world`s largest collection of fully-sequenced and annotated microbes from the crop microbiome, and we are screening this collection with validated, proprietary pipelines to discover new biologicals and trait genes. Partnerships with leading agricultural companies such as Syngenta and Genective accelerate our discovery process and allow us to deliver solutions to global markets. We employ 36 full-time and 14 part-time employees and will occupy a new state-of-the-art 30,000 square foot laboratory and greenhouse facility in early 2016. AgBiome`s products will help farmers combat many of the most important unsolved problems in agriculture, including insects, nematodes, and diseases. Our first product, a biological fungicide, has been submitted for regulatory review, with first sales anticipated in 2016.
Rainin Instrument is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CPS Instruments is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.
SkinMedica, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.